+Compare
EPIX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
260.19M

EPIX ESSA Pharma Forecast, Technical & Fundamental Analysis

a developer of small molecule drugs

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EPIX with price predictions
07:00 PM EST Dec 04, 2023

EPIX saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for EPIX moved out of overbought territory on November 29, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 52 similar instances where the indicator exited the overbought zone. In of the 52 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for EPIX moved out of overbought territory on November 06, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 05, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on EPIX as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EPIX turned negative on November 28, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EPIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EPIX broke above its upper Bollinger Band on November 02, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EPIX advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 220 cases where EPIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.553) is normal, around the industry mean (20.694). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.913).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EPIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EPIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 12%. For the same Industry, the average monthly price growth was 25%, and the average quarterly price growth was 27%. CMND experienced the highest price growth at 3,849%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was 81%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

EPIX is expected to report earnings to rise 29.41% to -21 cents per share on December 14

ESSA Pharma EPIX Stock Earnings Reports
Q3'23
Est.
$-0.22
Q2'23
Beat
by $0.02
Q1'23
Beat
by $0.05
Q4'22
Beat
by $0.08
Q3'22
Beat
by $0.11
The last earnings report on August 08 showed earnings per share of -17 cents, beating the estimate of -19 cents. With 42.33K shares outstanding, the current market capitalization sits at 260.19M.
A.I. Advisor
published General Information

General Information

a developer of small molecule drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
999 West Broadway Street
Phone
+1 778 331-0962
Employees
30
Web
https://www.essapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
COGLX11.65-0.06
-0.51%
AXS Alternative Value Investor
LAFCX16.20-0.10
-0.61%
Lord Abbett Affiliated C
DCLVX16.19-0.11
-0.67%
Dunham Large Cap Value C
SCVFX28.02-0.40
-1.41%
Allspring Small Company Value C
WSCYX16.91-0.26
-1.51%
Delaware Ivy Small Cap Growth Y

EPIX and

Correlation & Price change

A.I.dvisor tells us that EPIX and FATE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EPIX and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPIX
1D Price
Change %
EPIX100%
-0.56%
FATE - EPIX
32%
Poorly correlated
-7.09%
NKTX - EPIX
31%
Poorly correlated
-0.36%
PCVX - EPIX
31%
Poorly correlated
-0.94%
RNAZ - EPIX
25%
Poorly correlated
N/A
ARVN - EPIX
25%
Poorly correlated
-3.90%
More

Groups containing EPIX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPIX
1D Price
Change %
EPIX100%
-0.56%
north america
(undefined stocks)
19%
Poorly correlated
-1.14%
pharmaceuticals
(undefined stocks)
8%
Poorly correlated
-0.48%
small molecule
(undefined stocks)
-1%
Poorly correlated
-0.57%